Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by John Mascola and Olubukola Abiona.
John Mascola
Connection Strength
0.461
Olubukola Abiona
  1. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 08 10; 54(8):1869-1882.e6.
    View in: PubMed
    Score: 0.060
  2. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
    View in: PubMed
    Score: 0.060
  3. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021 05 12; 13(593).
    View in: PubMed
    Score: 0.059
  4. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines (Basel). 2021 Jan 21; 9(2).
    View in: PubMed
    Score: 0.058
  5. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci Rep. 2020 10 23; 10(1):18149.
    View in: PubMed
    Score: 0.057
  6. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 10 27; 33(4):108322.
    View in: PubMed
    Score: 0.057
  7. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
    View in: PubMed
    Score: 0.056
  8. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.